Effect of Off-Target Binding on 18F-Flortaucipir Variability in Healthy Controls Across the Life Span

Measuring early tau accumulation is important in studying aging and Alzheimer disease and is only as accurate as the signal-to-noise ratio of the tracer. Along with aggregated tau in the form of neurofibrillary tangles, 18F-flortaucipir has been reported to bind to neuromelanin, monoamine oxidase, calcifications, iron, leptomeningeal melanocytes, and microhemorrages. Although 18F-flortaucipir successfully differentiates healthy controls (HCs) from subjects with Alzheimer disease, variability exists in the cortical signal in amyloid-negative HCs. We aimed to explore the relationship between off-target binding signal and variability in the cortical signal in HCs. Methods: Subjects (n = 139) received 11C-Pittsburgh compound B (PIB) and 18F-flortaucipir PET scans and a magnetization-prepared rapid gradient echo MRI scan. PET frames were realigned and coregistered to the MR images, which were segmented using FreeSurfer. In amyloid-negative HCs (n = 90; age range, 21–94 y), 7 nonspecific or off-target binding regions were considered: caudate, pallidum, putamen, thalamus, cerebellar white matter, hemispheric white matter, and choroid plexus. These regions of interest were assigned to 3 similarly behaving groups using principle components analysis, exploratory factor analysis, and Pearson correlations for caudate, putamen, and pallidum (also correlated with age); thalamus and white matter; and choroid plexus. In amyloid-negative HCs with 11C-PIB and 18F-flortaucipir scans, correlations were calculated between white and gray matter before and after partial-volume correction. Results: The correlation between white and gray matter disappeared after partial-volume correction in 11C-PIB (r2 = 0) but persisted for 18F-flortaucipir (r2 = 0.27), demonstrating that the correlation between white and gray matter signal in 18F-flortaucipir is not solely due to partial-volume effects. A linear regression showed that off-target signal from putamen and thalamus together explained 64% of the variability in the cortical signal in amyloid-negative HCs (not seen in amyloid-positive HCs). Variability in amyloid-negative HCs but not amyloid-positive HCs correlated with white matter signal (unrelated to partial-volume effects) and age-related off-target signal (possibly related to iron load). Conclusion: The noise in the 18F-flortaucipir measurement could pose challenges when studying early tau accumulation.

[1]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[2]  W. Jagust,et al.  Considerations and code for partial volume correcting [18F]-AV-1451 tau PET data , 2017, Data in brief.

[3]  Alan A. Wilson,et al.  Distribution of Monoamine Oxidase Proteins in Human Brain: Implications for Brain Imaging Studies , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  N. Volkow,et al.  Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  Clifford R. Jack,et al.  An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.

[6]  J. Barrio,et al.  The Irony of PET Tau Probe Specificity , 2018, The Journal of Nuclear Medicine.

[7]  Valerie Treyer,et al.  Low cortical iron and high entorhinal cortex volume promote cognitive functioning in the oldest-old , 2017, Neurobiology of Aging.

[8]  Min-Ying Su,et al.  Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.

[9]  Dietmar R. Thal,et al.  Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.

[10]  Daniel R. Schonhaut,et al.  PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.

[11]  Hanna Cho,et al.  Off-Target 18F-AV-1451 Binding in the Basal Ganglia Correlates with Age-Related Iron Accumulation , 2018, The Journal of Nuclear Medicine.

[12]  A. Joshi,et al.  Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. , 2016, Brain : a journal of neurology.

[13]  Elizabeth C Mormino,et al.  Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant , 2012, NeuroImage.

[14]  Bradford C. Dickerson,et al.  Tau PET imaging in aging and early Alzheimer's disease , 2015 .

[15]  Charles DeCarli,et al.  Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. , 2015, Brain : a journal of neurology.

[16]  A. Fagan,et al.  Evaluation of Tau Imaging in Staging Alzheimer Disease and Revealing Interactions Between β-Amyloid and Tauopathy. , 2016, JAMA neurology.

[17]  B. Miller,et al.  Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders , 2018, JAMA.

[18]  D. Brooks,et al.  MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding , 2018, Molecular Imaging and Biology.

[19]  M. Citron,et al.  The tau positron‐emission tomography tracer AV‐1451 binds with similar affinities to tau fibrils and monoamine oxidases , 2018, Movement disorders : official journal of the Movement Disorder Society.

[20]  Keith A. Johnson,et al.  18F-Flortaucipir Binding in Choroid Plexus: Related to Race and Hippocampus Signal. , 2018, Journal of Alzheimer's disease : JAD.

[21]  M. Mintun,et al.  Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease , 2016, The Journal of Nuclear Medicine.

[22]  H. Kolb,et al.  [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.

[23]  Nick C Fox,et al.  Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias , 2016, Alzheimer's & Dementia.

[24]  Keith A. Johnson,et al.  Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.

[25]  A. Evans,et al.  Correction for partial volume effects in PET: principle and validation. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[26]  Christopher G Schwarz,et al.  Widespread brain tau and its association with ageing, Braak stage and Alzheimer's dementia. , 2018, Brain : a journal of neurology.

[27]  N. Turro,et al.  New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals , 2008, Proceedings of the National Academy of Sciences.

[28]  M. Mintun,et al.  Flortaucipir F 18 Quantitation Using Parametric Estimation of Reference Signal Intensity , 2017, The Journal of Nuclear Medicine.

[29]  Rik Ossenkoppele,et al.  Quantification of Tau Load Using [18F]AV1451 PET , 2017, Molecular Imaging and Biology.

[30]  Keith A. Johnson,et al.  Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson’s case , 2017, Acta Neuropathologica Communications.

[31]  M. Bobinski,et al.  Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.

[32]  William J. Jagust,et al.  Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease , 2017, NeuroImage.

[33]  Suzanne L Baker,et al.  Reference Tissue–Based Kinetic Evaluation of 18F-AV-1451 for Tau Imaging , 2017, The Journal of Nuclear Medicine.

[34]  M. Mintun,et al.  Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects , 2017, The Journal of Nuclear Medicine.

[35]  Brian A. Gordon,et al.  Widespread distribution of tauopathy in preclinical Alzheimer's disease , 2018, Neurobiology of Aging.